This study aims to address the challenge of predicting the efficacy of targeted and immunotherapy in lung cancer patients. By utilizing two DCE-MRI images-one before treatment and one after one treatment cycle-along with the patients' clinical and pathological information, we aim to achieve accurate prediction of the therapeutic efficacy of targeted and immunotherapy in lung cancer patients.
Tumor size greater than 2 cm
Age between 18 and 75 years
Presence of MRI contraindications (e.g., metal implants, pacemaker implantation, etc.)
Allergy to gadolinium contrast agents
Lesions difficult to delineate on images due to conditions such as atelectasis or diffuse lesions
Single group
Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer
Diagnostic testChest MRI scans outside of the standard treatment protocol
Tumor treatment response evaluation
This study aims to evaluate tumor treatment response using the RECIST V1.1 criteria, based on CT images taken within one week before treatment and two weeks after treatment completion.
Click on the lead sponsor to view all of their trials.
